Dr. Tim Miller (@TimMillerNeuro@WashUNeurology) recently shared new Phase 3 #tofersen results at ENCALS 2022. Check out the full dataset here: https://t.co/9OUu4kQI5i
On behalf of The VALOR and OLE Working Group, Timothy Miller presented new 12 month data for Tofersen at the recent ENCALS 2022 meeting. https://t.co/wVJGHeSg1H
It was an eventful weekend for Dr. Miller in Chicago. In addition to receiving the Potamkin Award, he was inducted as a new member into the Association of American Physicians @AAPcouncil. Congratulations, Dr. Miller!
"I am honored and deeply grateful to the Potamkin Family, the American Brain Foundation, and the American Academy of Neurology for recognizing our work with the 2026 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases" – Dr. Miller #AANAM@ABFbrain@AANmember
I am honored to be a part of @NIHprevents' next #PreventionInFocus webinar on October 10 at 2:00 p.m. ET, to discuss the promise of strategies to prevent Alzheimer’s disease. Register at https://t.co/YWF4U6p2nu
We're breaking our posting silence to congratulate Miller Lab graduate student @MiweiHu on her excellent poster presentation at the @RCFNeuro Tau Consortium last week. Miwei discussed the effects of #tau splicing on #sleep in #tauopathy. Keep up the great work!
Really excited about our latest preprint, where we uncovered a neuroprotective role for neuronal polyunsaturated fatty acids in FTD and ALS. Led by @AshlingGiblin and @AlexCammack https://t.co/NIm2FmGZV5 1/9
Thank you @MtlSyndrome for your generous support! We look forward to working with you on this exciting project to develop a potential treatment for Mitchell Syndrome!
https://t.co/uQ2gDofsHG
Congratulations to our three #WashUMed faculty members elected to the National Academy of Medicine: Michael S. Avidan, MBBCh, Sarah K. England, PhD, and Timothy Miller, MD, PhD. Learn more about their groundbreaking work here: https://t.co/FJb2cDq2o1
.@TimMillerNeuro This Is Your Life! Happy to host a virtual reunion of Miller Lab alumni to celebrate the FDA approval of #tofersen for SOD1 #ALS. Congrats to Tim and everyone involved!
BREAKING: the FDA has approved a new drug called toferson for a rare form of ALS caused by mutations in the gene SOD1. #WashUMed researcher @MillerLabNeuro, MD, PhD, led the international clinical trials. @ALSCenterWashU@biogen
https://t.co/cLZipFm4ui
New SOD1 #ALS drug candidate, #tofersen, is up for review by an FDA Advisory Committee on Wednesday, March 22nd from 9:15 am - 6 pm EST. You can watch the meeting virtually here: https://t.co/3LBmtC48JS
5. More studies and randomized controlled trials in humans will be needed to understand the potential neuroprotective benefit of #lovastatin to ALS patients.
What if we could identify treatments for #ALS from the drugs people already take? 💊
That’s exactly what our latest collaborative work tested. Here are a few exciting takeaways from the full study, published in @ANA_journals:
https://t.co/3LdM4rQEXy
Please join us in congratulating our 2023 winners of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research and the Rainwater Prize for Innovative Early-Career Scientist. Click to read about recipients! https://t.co/cfyvKQsHJZ
#rainwaterprize
“They are exceptional change makers."
Neuroscience majors Sam Norwitz and Ephraim Oyetunji of #WashU23 were finalists for the Rhodes Scholarship, one of the world’s most prestigious academic honors, to study at the University of Oxford in England. https://t.co/GSRhlF14Kh
Read our latest paper out in @NatureComms on genotype-phenotype correlations in SOD1-#ALS. This is the largest study of its kind for #SOD1 variants. Great work led by @opie_martin and @AlfredoIacoange at @KingsCollegeLon !
https://t.co/UTs7b7CrW5